title: Neuropeptide Y reduces the expression of PLCB2, PLCD1 and selected PLC genes in cultured human endothelial cells.
abstract: Endothelial cells (EC) are the first elements exposed to mediators circulating in the bloodstream, and react to stimulation with finely tuned responses mediated by different signal transduction pathways, leading the endothelium to adapt. Neuropeptide Y (NPY), the most abundant peptide in heart and brain, is mainly involved in the neuroendocrine regulation of the stress response. The regulatory roles of NPY depend on many factors, including its enzymatic processing, receptor subtypes and related signal transduction systems, including the phosphoinositide (PI) pathway and related phospholipase C (PI-PLC) family of enzymes. The panel of expression of PI-PLC enzymes differs comparing quiescent versus differently stimulated human EC. Growing evidences indicate that the regulation of the expression of PLC genes, which codify for PI-PLC enzymes, might act as an additional mechanism of control of the PI signal transduction pathway. NPY was described to potentiate the activation of PI-PLC enzymes in different cell types, including EC. In the present experiments, we stimulated human umbilical vein EC using different doses of NPY in order to investigate a possible role upon the expression PLC genes. NPY reduced the overall transcription of PLC genes, excepting for PLCE. The most significant effects were observed for PLCB2 and PLCD1, both isoforms recruited by means of G-proteins and G-protein-coupled receptors. NPY behavior was comparable with other PI-PLC interacting molecules that, beside the stimulation of phospholipase activity, also affect the upcoming enzymes' production acting upon gene expression. That might represent a mode to regulate the activity of PI-PLC enzymes after activation.
authors.affiliation: Department Organi di Senso, Policlinico Umberto I, Faculty of Medicina e Odontoiatria, Sapienza University of Rome, viale del Policlinico 155, 00185, Rome, Italy, ritalovasco@hotmail.it.
authors.forename: V R
authors.initials: VR
authors.lastname: Lo Vasco
authors.forename: M
authors.initials: M
authors.lastname: Leopizzi
authors.forename: C
authors.initials: C
authors.lastname: Puggioni
authors.forename: C
authors.initials: C
authors.lastname: Della Rocca
authors.forename: R
authors.initials: R
authors.lastname: Businaro
mesh_terms: D015153:Blotting, Western; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004794:Enzyme Repression; D061307:Human Umbilical Vein Endothelial Cells / Q000187:drug effects* / Q000201:enzymology; D006801:Humans; D009478:Neuropeptide Y / Q000494:pharmacology*; D054799:Phospholipase C beta / Q000235:genetics / Q000378:metabolism*; D054803:Phospholipase C delta / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: D009478:Neuropeptide Y; D012333:RNA, Messenger; C518033:PLCB1 protein, human; C518024:PLCD1 protein, human; D054799:Phospholipase C beta; D054803:Phospholipase C delta